A genetic switch that activates immune cells as they fight tumours: this is the new strategy developed by an international research team coordinated by Velia Siciliano at the Istituto Italiano di Tecnologia (IIT – Italian Institute of Technology) in Naples and described in the scientific journal Nature Communications. The study marks another step towards engineering precise and more effective synthetic immunotherapies against solid tumours, such as melanoma and breast cancer.

Cirrhosis once viewed as irreversible, can improve after effective treatment, but recovery may not be complete or permanent. Researchers from China propose recognizing recompensation as a distinct treatment-related disease state and distinguishing stable from unstable recovery. Evidence across liver diseases shows that recompensation improves outcomes compared with persistent decompensation, while some patients later relapse. The framework could support more consistent research, clinical assessment, and long-term surveillance for patients recovering after cirrhosis treatment.

This authoritative review synthesizes 5 years of pivotal clinical and translational advances in esophageal cancer (EC), encompassing molecular pathogenesis, genomic and epigenetic landscapes, targeted therapeutic modalities and the tumor immune microenvironment. It underscores breakthroughs of immunotherapy in EC management while acknowledging slower progress in targeted treatments. Promising future directions include TKIs, CDK4/6 inhibitors, PI3K/AKT/mTOR pathway modulators, epigenetic regulators, ADCs, and rational combination strategies to overcome drug resistance and improve long-term patient survival outcomes.

BUFFALO, NY - October 14, 2026 – A new research paper was published in Volume 17 of Oncotarget on October 12, 2026, titled “Integrative pan-cancer analysis of AKT1 and structure-based drug design by buckwheat derived compounds.”

CSHL Assistant Professor Semir Beyaz and colleagues have shown that transcription factor PPARD can promote the fitness of both cancer and immune cells. Their research could help make CAR T-cell therapy effective against colorectal cancer and lead to new treatment strategies for endometriosis, among other conditions.

What if the same particle beam could both destroy a tumor and reveal, in real time, where the treatment is actually reaching? A new mixed-beam approach combines carbon ions for therapy with helium ions for monitoring — and a new method now makes it possible to check the beam composition without interrupting it.

This review argues that the central obstacle to the clinical translation of RNA 5-methylcytosine (m5C) in cancer is measurement, not biological plausibility. Although m5C regulates RNA maturation, export, stability, translation and decay, and altered m5C pathways have been linked to tumor progression, immune regulation and resistance phenotypes, current platforms support non-equivalent claims. LC-MS/MS provides calibrated bulk quantification but destroys site information; conversion and deaminase chemistries resolve candidate nucleotides but remain background-limited and largely semiquantitative; antibody enrichment and writer trapping yield regions or enzyme-dependent substrates without native site fractions; nanopore calls are model- and context-dependent. These limitations are amplified near the noise floor in FFPE tissue, small biopsies, plasma and extracellular-vesicle RNA, where a missing signal is a no-call rather than an unmodified cytosine. The authors conclude that no platform is yet adequate as a standalone reportable assay. Translation requires an intended-use-specific measurand, matrix-matched controls, calibrated site fractions, locked wet-laboratory and bioinformatic procedures, explicit limits of blank, detection and quantification, followed by independent clinical validation and comparison with established tests. Biological heterogeneity, tumor attribution, incremental value, feasibility and clinical utility also require prospective evaluation in parallel.

In a new, paradigm-shifting study in ovaries from 28 women, scientists at Northwestern University and the Buck Institute for Research on Aging found in the decades well past menopause, the ovary remains biologically active and continues to remodel with age, showing increased inflammation and changes in tissue structure. The study also found a molecular link between ovarian aging and cancer.

“In the ovary, we reach a point of no return with respect to fertility in which it's no longer producing eggs, and I would venture to say most people assume those ovaries are just sitting there doing nothing, similar to the appendix,” said co-corresponding author Francesca Duncan, associate professor of reproductive science in medicine at Northwestern University Feinberg School of Medicine. “But that's what makes this study very different.” 

The findings challenge the notion that the ovary is an innocent bystander after reproduction ends, raising new questions about whether it could play a more active role in aging and chronic disease in women.